ICO News

Blockchain And Early Cancer Detection


ARNA Genomics (Biomarker LLC) is Russian technologic company, situated in Skolkovo, which is dealing  with the problem of early cancer detection. It’s coming to  the ICO market with the ARNA Panacea project, built on blockchain technology. According to general creators’ idea ARNA Panacea is going to become a new platform for interaction between patients, clinics, certified laboratories, pharmaceutical companies, researchers, investors and certification authorities.

About  The Ecosystem


     ARNA Panacea plans to release ARNA tokens, which will be used for payments within the system by all platform members. Thus, patients will be able to pay tokens for tests of early cancer detection.  They can also earn by taking part in clinical researches, for example, by providing the results of their analyzes, even if anonymously. Sponsors will be able to invest tokens into clinical researches of the latest technologies and products and   gain a percentage of  commercialization   of test results. And scientists will receive a reward for the successful research. Also, all members of the platform will be able to exchange tokens and, if necessary, withdraw funds from the system.

   About The Product

The first product of the company, which will be presented on the platform, will be ARNA BC. This is a test for the early detection of breast cancer. The advantage of this test lies in  its relative cheap price, greater sensitivity and selectivity for cancer cells. This test was developed by Biomarker LLC.

In 2015, clinical and laboratory studies started in Russia. After the ICO, it is planned to launch clinical studies of the ARNA BC test in the United States and undergo a registration procedure in the FDA (Food and Drug Administration). It is also planned to continue development of  new tests to determine other types of cancer. The value of these tests lies in the early detection  of cancer cells, which gives a higher chance of recovery.

About ICO

     ARNA Genomics will hold  the ICO on November 19th up to December 3rd. The ICO will only release 50% of all tokens, which will be released partially every six months during 3 years.  Half of the amount  that ARNA BC plans to earn, will go to clinical researches under the supervision of the FDA (Food and Drug Administration). At the same time, the process of test registration in Russia will be launched. In the future, it is planned to promote ARNA BC in the market of Europe and China.

Tokens’ distribution:

  • 50% ICO
  • 25% ecosystem development
  • 24% retained for the team
  • 1% coverage of ICO costs

Funds distribution received from TDE

  • ARNA BC — 50%
  • ARNA Panacea — 17%
  • research developments — 14%
  • Operating costs, including marketing — 13%
  • Costs for lawyers — 5%

For VIP Investors

Holders of more than 500,000 tokens will receive VIP status. This category of investors will receive a number of additional opportunities. So, for example, they will be able to sign an official agreement. In the future, the company is considering the possibility of entering an IPO, what will enable VIP investors to become shareholders and open up new rights and opportunities for them.

The Team

The ARNA Panacea project attracts attention by a very strong team, which includes the creator of the ARNA BC test, doctors of science, experts in biotechnology, genetic engineering, IT and business. Also, the project is “strengthened” by advisors: people with experience in introduction of pharmacological products, passing through various stages of certification, blockchain specialists, independent experts.


ARNA Genomics came to the ICO market not with “hollow” words, but a working prototype. So, the ARNA BC test is created to reduce the deaths number  due to early cancer detection. The company conducted a market research, the results of which favour the ARNA BC.  It is worth noticing that  the creation of a decentralized platform in the healthcare system solves several problems, allowing to reduce the cost of services, to speed up the process of introducing new techniques and medicines, and to regain the trust of patients. The implementation schedule of the project is ambitious and a professional trustworthy  team is gathered to put it into effect. Potential risks include possible difficulties during the process of test certification  in the FDA and the problems connected with coming into the market.


Source: en.bit.news
View original post

Show More

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button